MARKET

SLP

SLP

Simulations Plus Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

54.28
+3.00
+5.85%
Opening 13:24 07/07 EDT
OPEN
52.54
PREV CLOSE
51.28
HIGH
56.10
LOW
50.97
VOLUME
228.39K
TURNOVER
8.59M
52 WEEK HIGH
57.96
52 WEEK LOW
35.18
MARKET CAP
1.10B
P/E (TTM)
97.77
1D
5D
1M
3M
1Y
5Y
--Craig Hallum Raises Simulations Plus' Price Target to $60 From $55, Buy Rating Kept
MT Newswires · 4h ago
Simulations Plus (SLP) Q3 Earnings and Revenues Surpass Estimates
Simulations Plus (SLP) delivered earnings and revenue surprises of 17.65% and 5.94%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 20h ago
Simulations Plus Q3 EPS $0.20 Beats $0.17 Estimate, Sales $15.00M Beat $14.33M Estimate
Simulations Plus (NASDAQ:SLP) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.17 by 17.65 percent. This is a 11.11 percent increase over earnings of $0.18 per share from the
Benzinga · 21h ago
Simulations Plus Stock Scores Composite Rating Move Up To 96
The IBD SmartSelect Composite Rating for Simulations Plus stock rose from 94 to 96 Wednesday. The medical software stock has 94 Relative Strength Rating. The new rating is a sign the stock is outpacing 96% of all stocks when it comes to the most important ...
Investor's Business Daily · 22h ago
Earnings Scheduled For July 6, 2022
  Companies Reporting After The Bell • Saratoga Investment (NYSE:SAR) is expected to report quarterly earnings at $0.53 per share on revenue of $19.21 million.
Benzinga · 1d ago
Notable earnings after Wednesday's close
SAR, <a href="https://seekingalpha.com/symbol/SLP?utm_medium=referral&utm_source=webull.com" title="Simulations ...
Seekingalpha · 1d ago
Simulations Plus Q3 2022 Earnings Preview
Simulations Plus (NASDAQ:SLP) is scheduled to announce Q3 earnings...
Seekingalpha · 1d ago
Preview: Simulations Plus's Earnings
Simulations Plus (NASDAQ:SLP) is set to give its latest quarterly earnings report on Wednesday, 2022-07-06. Here's what investors need to know before the announcement. Analysts estimate that Simulations Plus will report an earnings per share (EPS) of $0.17...
Benzinga · 2d ago
More
No Data
Learn about the latest financial forecast of SLP. Analyze the recent business situations of Simulations Plus Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
50.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SLP stock price target is 60.00 with a high estimate of 75.00 and a low estimate of 54.00.
High75.00
Average60.00
Low54.00
Current 54.28
EPS
Actual
Estimate
0.050.110.160.21
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 193
Institutional Holdings: 15.65M
% Owned: 77.45%
Shares Outstanding: 20.21M
TypeInstitutionsShares
Increased
53
439.47K
New
14
80.95K
Decreased
53
330.25K
Sold Out
18
275.38K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.36%
Healthcare Equipment & Supplies
+0.38%
Key Executives
Chairman/Director
Walter Woltosz
Chief Executive Officer
Shawn O'Connor
Chief Financial Officer/Secretary
William Frederick
Corporate Executive
John DiBella
Corporate Executive
Jill Fiedler-kelly
Corporate Executive
Brett Howell
Independent Director
Sharlene Evans
Independent Director
Lisa LaVange
Independent Director
John Paglia
Independent Director
Daniel Weiner
No Data
No Data
About SLP
Simulations Plus, Inc. is a developer of drug discovery and development software for mechanistic modeling and simulation, for machine-learning-based prediction of properties of molecules from their structure, and is exploring the application of its machine-learning technologies in other industries, including aerospace/military and general healthcare. The Company offers its products and services through two business segments, which include Simulations Plus, Inc. and Cognigen Corporation. Cognigen Corporation is the subsidiary of the Company. Its pharmaceutical/chemistry software is used by various companies, such as pharmaceutical, biotechnology, agrochemical, and food industry companies and to regulatory agencies for use in the conduct of industry-based research. Its clinical-pharmacology-based consulting services include pharmacokinetic and pharmacodynamics modeling, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions.

Webull offers kinds of Simulations Plus Inc stock information, including NASDAQ:SLP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLP stock methods without spending real money on the virtual paper trading platform.